| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8568f29a3ec5d8a3d42f63dd50f85369 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-063 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate |
1993-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd40c804a7c89a0559842139cb94b5b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_567218cc515aa6308c58799ecb23c4cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_029e7ff92f5b9a8c72edfb6e57e83be8 |
| publicationDate |
1994-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H0680568-A |
| titleOfInvention |
Methods to reduce or prevent toxicity associated with antiretroviral therapy |
| abstract |
(57) [Summary] (Modified) [Objective] To provide a method for reducing or preventing the toxicity associated with antiretroviral therapy. In a preferred embodiment, the antiretroviral therapy comprises AZT or DDI. Preferably, the composition for stimulating intracellular glutathione levels is L- 2-oxothiazolidine-4-carboxylate. It is also HIV positive, comprising administering antiretroviral therapy to the patient and administering to the patient an intracellular glutathione stimulator in an amount sufficient to reduce the toxicity of the antiretroviral therapy. The method comprises treating a patient or a patient having AIDS. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2001511770-A |
| priorityDate |
1992-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |